Onyx Kicks Off Pipeline Expansion By Buying TS Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
Preclinical oncologic in-licensed from BTG offers opportunity in ovarian, lung, breast and colorectal cancers, biotech says.
You may also be interested in...
No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma
Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.
No Joy In Bayer/Onyx’s Phase III With Nexavar For Melanoma
Second sorafenib failure comes three months after Synta/GlaxoSmithKline’s elesclomol blow-up in the tough-to-crack cancer.
Gilead, Myriad Top J.P. Morgan’s 2009 Short List
FDA decision on AMAG’s iron therapy ferumoxytol is also key event for small-cap biotech this year.